Varieties of Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is the most important cause of the adrenogenital syndrome in infancy and childhood. It is a classic example of an 'inborn error of metabolism' and represents the clinical expression of a hereditary defect in the biosynthesis of cortisol. Studies on patients with this disorder have enriched our knowledge on the biosynthesis and metabolism of adrenocortical steroids, the psychosexual orientation and maturation in man and the effects of androgens on growth and skeletal maturation.
At least three and possibly five hereditary defects in the biosynthesis of cortisol have been described so far. An impaired biosynthesis of cortisol explained by a relative defect of 21hydroxylation, 1 1-hydroxylation, 17-hydroxylation or 3p-dehydrogenation will ultimately lead to compensatory hypertrophy of the adrenal cortex (congenital adrenal hyperplasia) by excessive corticotrophin secretion via the negative feedback action between the anterior pituitary gland (ACTH) and the adrenal cortex (cortisol). A variant of congenital adrenal hyperplasia has been described as lipoid adrenal hyperplasia. This disorder may be due to a very early defect in corticosteroid biosynthesis between cholesterol and pregnenolone (20a-hydroxylase defect ?).
In patients with lipoid adrenal hyperplasia, 17-hydroxylation defect and 3p-dehydrogenation defect also the biosynthesis of androgens (in the adrenal cortex and gonads) is more or less impaired.
During recent years more accurate methods for estimation of the production and excretion of the mineralocorticosteroids have become available and at least two hereditary defects in the biosynthesis of aldosterone have been found. Infants and children with the salt-losing variant of CAH (21-hydroxylation defect) have impaired production of cortisol and aldosterone as well and hereditary defects which involve only the biosynthesis of aldosterone have been described (18-oxidation defect). The diagnosis of a specific defect is greatly facilitated by studying the increased production and excretion of steroid precursors (and their metabolites) which accumulate before the enzyme block.
Congenital adrenal hyperplasia (CAH) is the most important cause of the adrenogenital syndrome in infancy and childhood. The typical clinical symptoms in affected male and female patients are caused by the excessive secretion of adrenal androgens associated with the most common variants of CAH: the 21-and 11hydroxylation defects. Generally abnormalities of the genitalia externa are present at birth in the female patient (female pseudohermaphroditism). The increased urinary excretion of 17-ketosteroids is mainly due to increased secretion of C19precursors as DHA and androstenedione. However, these adrenal androgens have relatively weak-biologic potency, and cannot explain the symptoms of virilization in patients with CAH. Recently increased production and excretion of testosterone in patients with CAH (21-hydroxylation defect) have been reported.
Patients with the 1 1-hydroxylation defect generally demonstrate hypertension which may be the result of the production of large amounts of deoxycorticosterone. Otherwise they are clinically not different from patients with 21-hydroxylation defect.
In about 30 % ofthe patients with a 21-hydroxylation defect the salt-losing syndrome is present: hyponatrw,mia, hyperkalaemia and metabolic acidoses, changes typical of Addison's disease. Using isotope dilution techniques, several investigators reported low aldosterone secretion rates in patients with the salt-losing variant of CAH (21-hydroxylation defect).
Patients with the two variants of the 21hydroxylation defect, with and without salt loss, are different genotypes. We have suggested that biochemically too both types of patients represent different types of the same disorder. The differences in production of cortisol and aldosterone in both groups of patients, before and during stimulation with ACTH and before and during salt deprivation respectively can be explained by two different genetically controlled changes in the same 21-hydroxylation enzyme or in different steps ofthe 21-hydroxylation mechanism.
Salt loss in patients with the salt-losing type of CAH (21-defect) can be adequately explained by the severely impaired production of aldosterone. Progesterone and 1 7a-hydroxyprogesterone, which are produced in increased amounts in the case of a 21-hydroxylation defect in the biosynthesis of cortisol, antagonize the renal tubular effect of mineralocorticoids, and these steroid precursors may further limit renal conservation of sodium in patients with CAH (21-defect). This may be particularly the case in newborn infants with the 'non salt-losing' variant of CAH and normal aldosterone production who sometimes are in negative sodium balance when on a low sodium intake. Increased aldosterone secretion rates have been reported in older patients with the 'non salt-losing variant'. It might well be that 'non salt losers', who are never treated or are without treatment for a long time, produce increased amounts of aldosterone as a 'compensation' for the mineralocorticoid antagonizing effect of 17-hydroxyprogesterone.
A few patients with 3,8-dehydrogenation defect have been reported and most of them were 'salt losers'. In this early defect in the biosynthesis of adrenocortical steroids also the biosynthesis of androgens is impaired. The clinical symptoms in newborn infants may be completely different from those in babies with 21-hydroxylation defect. Affected males may demonstrate the peculiar picture of incomplete masculine external genital development (male pseudohermaphroditism) and affected females may have normal external genitalia. The classic animal experiments of Jost have shown that an androgen, probably testosterone, and a 'male inductor substance', most likely not a steroid, produced by the foetal testes are necessary for normal masculine genital organogenesis. Castration of the rabbit foetus in an early undifferentiated stage resulted in complete feminine external genitalia. In patients with 3p-dehydrogenation defect histochemical studies indicated markedly reduced 3,-hydroxysteroid dehydrogenase activity in the testes. Impairment of the testicular biosynthesis of androgens during early embryonic development can explain these findings of male pseudohermaphroditism in male babies with this rare variant of CAH. A clinically similar form has been described as lipoid adrenal hyperplasia. The cases reported up to the present were all salt losers and the outcome was invariably fatal. Lipoid adrenal hyperplasia may be due to a very early defect in the corticosteroid biosynthesis between cholesterol and pregnenolone (20ahydroxylase defect ?).
Male patients with 17-hydroxylation defect in the biosynthesis of steroids most likely will also exhibit male pseudohermaphroditism. Although some patients with a postulated 17-hydroxylation defect have been described, more detailed studies are needed.
It is very likely that the salt loss in infants with these 'early' defects in the biosynthesis of corticosteroids is also caused by severe hypoaldosteronism.
The 18-oxidation enzyme step affects only the biosynthesis of aldosterone between corticosterone and aldosterone. A hereditary 18-oxidation defect with severely impaired biosynthesis ofaldosterone could be expected to result clinically in a salt-losing syndrome without an increased elaboration of adrenal androgens by ACTH stimulation. Some years ago we reported 3 related children with a salt-losing syndrome in infancy and a urinary corticosteroid excretion pattern highly suggestive for an 18-hydroxylation defect in the biosynthesis of aldosterone.
A few patients with a 1 8-dehydrogenation defect have been reported in the literature.
Genetic studies in patients with CAH (most of them with 21-hydroxylation defect) indicate that the defects in the biosynthesis of adrenocortical steroids are due to recessive autosomal heredity with clinical expression in the homozygous state. There is no true difference in the sex ratio.
Up to the present it has not been possible to detect the heterozygous carrier of the gene(s). The incidence of the gene(s) is probably between 1:50 and 1 :100 in different populations.
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The pedigree of our family with the 18-oxidation defect indicates the same recessive autosomal heredity as the other defects in the biosynthesis of adrenocortical steroids. The most common form of congenital adrenal hyperplasia (CAH) is that due to diminished activity of the adrenal 21-hydroxylase enzyme system. The presentation is that of cortisol deficiency with or without salt loss, and increased pregnanetriol excretion. Earlier studies (Galal et al. 1968 ) have indicated that the 21-hydroxylation defect is greater in salt losers than in non salt losers, suggesting that the 17a-hydroxyprogesterone secretion rate, and in consequence pregnanetriol excretion, is dependent upon the degree of 21-hydroxylase deficiency. An enhanced production of A' androstenedione and testosterone is recognized in this condition (Horton & Frasier 1967) .
Salt losers and non salt losers also show virilization which may be accounted for by the enhanced testosterone production and/or target organ sensitivity. It is known that 17a-hydroxyprogesterone will give rise not only to pregnanetriol, but also to A4 androstenedionean important precursor to testosterone. We have therefore attempted to show whether plasma testosterone levels are ACTH dependent and related to levels of plasma A4 androstenedione and whether a direct relationship exists between urinary testosterone and pregnanetriol excretion.
Untreated patients: Of 6 untreated patients demonstrating elevated plasma testosterone levels 5 had levels in the adult male range and one in the adult female range (69-800 ng/100 ml plasma). One non salt-losing untreated patient showed a further transitory increase of plasma testosterone and cortisol at 2 hours after a single intramuscular injection (40 units) of ACTH (Fig 1) . Suppression ofplasma testosterone in this patient to 50 ng/100 ml and plasma cortisol to 6 pg/100 ml was achieved after a one-day course (0-25 mg 6-hourly) of dexamethasone. The plasma A' androstenedione levels in the same patient after ACTH stimulation were even greater than the correspondingtestosterone levels and exceeded the normal adult male and female ranges (basal 724, 2 hours after ACTH 1,666, and 4 hours after ACTH 3,000 ng/100 ml). Treated patients: Further studies in treated patients produced the following results. Seven patients with CAH (4 salt losers and 3 non salt losers), maintained on different doses of glucocorticoids, were given a single intramuscular injection (40 units) of ACTH. Plasma testosterone and cortisol levels were then measured 2-6 hours after ACTH. Under these conditions, no evidence could be elicited for either testosterone or cortisol production, suggesting pituitary/ adrenal suppression due to steroid therapy.
In contrast 9 patients with CAH maintained on dexamethasone and one untreated non salt-losing
